MUFG Securities EMEA plc acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 40,000 shares of the pharmaceutical company’s stock, valued at approximately $6,082,000.

Several other institutional investors have also added to or reduced their stakes in VRTX. Jennison Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 253.8% during the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after buying an additional 3,626,368 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in shares of Vertex Pharmaceuticals by 1,384.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after buying an additional 1,114,939 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Vertex Pharmaceuticals by 9,422.3% in the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock worth $135,829,000 after purchasing an additional 883,998 shares during the last quarter. AJO LP purchased a new position in Vertex Pharmaceuticals in the second quarter worth about $71,956,000. Finally, Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after purchasing an additional 504,982 shares during the last quarter. 92.42% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “MUFG Securities EMEA plc Acquires New Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/mufg-securities-emea-plc-acquires-new-stake-in-vertex-pharmaceuticals-incorporated-vrtx/1722224.html.

In other news, COO Ian F. Smith sold 75,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $145.06, for a total value of $10,879,500.00. Following the completion of the transaction, the chief operating officer now owns 114,188 shares in the company, valued at approximately $16,564,111.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Stuart A. Arbuckle sold 221 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $147.29, for a total value of $32,551.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 220,315 shares of company stock worth $32,107,270. Corporate insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up $1.93 during trading hours on Thursday, reaching $147.04. The company’s stock had a trading volume of 897,411 shares, compared to its average volume of 1,805,590. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The company has a market cap of $36,698.73, a P/E ratio of 241.85, a price-to-earnings-growth ratio of 3.69 and a beta of 1.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 50.38%. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same quarter in the previous year, the company posted $0.16 EPS. The company’s revenue was up 39.7% compared to the same quarter last year. equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.

Several research analysts have issued reports on the company. Royal Bank Of Canada reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. HC Wainwright reissued a “hold” rating and issued a $85.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. Finally, Maxim Group reissued a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have issued a buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $173.15.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.